Document:

EXHIBIT 4.26

 

FORM OF AMENDMENT TO NON-QUALIFIED STOCK
OPTION AGREEMENT

UNDER THE PEREGRINE PHARMACEUTICALS, INC.

2009 STOCK INCENTIVE PLAN

(NON-EMPLOYEE DIRECTORS)

 

This Amendment (“Amendment”)
to Non-Qualified Stock Option Agreement (the “Agreement”) dated as of __________, is between Peregrine Pharmaceuticals,
Inc., a Delaware corporation (the “Company”), and ________, (the “Optionee”).

 

WHEREAS, on ___________,
Optionee was awarded an option to purchase ________ shares of the Company’s common stock pursuant to the Peregrine Pharmaceuticals,
Inc. 2009 Stock Incentive Plan, as amended from time to time (the “Plan”), as set forth in the Award Agreement;

 

WHEREAS, capitalized terms
used but not defined herein shall have the meanings ascribed to them in the Plan;

 

WHEREAS, pursuant to clause
C.2.(i) of Section 1 of Article Two of the Plan, the Plan Administrator (which means the Compensation Committee of the Board) has
the authority to extend the period of time for which an outstanding option is to remain exercisable following an Optionee’s
cessation of Service;

 

WHEREAS, on April 24, 2015,
the Compensation Committee of the Company’s Board of Directors approved an amendment to all outstanding options to non-employee
members of the Company’s Board of Directors extending the exercise period following a Termination of Employment (or Service)
for any reason to two (2) years (the “Extended Exercise Period”); and

 

WHEREAS, Company and Optionee
desire to enter into this Amendment in order to restate Section 7 of the Agreement to reflect the Extended Exercise Period.

 

NOW, THEREFORE, the parties
hereto hereby agree as follows:

 

1.            Section
5 of the Agreement is hereby amended and restated in its entirety as follows:

 

“5. Termination of
Employment; Death. Upon termination of Optionee’s employment with or status as a consultant to, the Company for any
reason, the Options will immediately terminate and expire, except as provided in paragraphs (a) or (b) of this Section 5.

 

(a) If
Optionee resigns as an employee of, or consultant to, the Company with the Company's prior written consent, or if the Company
terminates Optionee's employment by the Company without Cause (as defined herein), the Option will be exercisable but only to
the extent it was exercisable at the time of such termination or resignation and only until the earlier of the
expiration date of the Option, determined pursuant to Section 2 of this Agreement, or the expiration of two (2) years
following such termination or resignation.

 

(b) If
Optionee dies or becomes Permanently Disabled while employed by, or rendering services as a consultant to, the Company or
after Optionee's employment or status as a consultant to the Company terminates but during a period in which the
Option is exercisable pursuant to paragraph (a) of this Section 5, the Option will be exercisable but only to the
extent it was exercisable at the time of death and only until the earlier of the expiration date of the Option, determined
pursuant to Section 2 of this Agreement, or the expiration of two (2) years following the date of Optionee's death or the
date Optionee becomes Permanently Disabled.”

 

2.            The remaining terms and conditions of
the Agreement shall survive this Amendment and will continue in full force and effect.

 

IN WITNESS WHEREOF, the
parties hereto have executed this Amendment as of the date and year first written above.

 

PEREGRINE PHARMACEUTICALS,
INC.

 

 

 

By:________________________________

 

 

 

OPTIONEE:

 

 

__________________________________

Signature

 

Name:____________________________

 

Social Security Number:

 

_________________________________EXHIBIT 4.27

 

FORM OF aMENDMENT
TO STOCK OPTION AWARD AGREEMENT

UNDER THE PEREGRINE PHARMACEUTICALS,
INC. 

2011 STOCK INCENTIVE PLAN

(NON-EMPLOYEE DIRECTORS) 

 

This Amendment (“Amendment”)
to Stock Option Award Agreement (“Award Agreement”) is between Peregrine Pharmaceuticals, Inc. (“Company”)
and ________________________ (the “Optionee”), and is effective as of the ____ day of _____________, 2015.

 

WHEREAS, on ___________,
Optionee was awarded an option to purchase ________ shares of the Company’s common stock pursuant to the Peregrine Pharmaceuticals,
Inc. 2011 Stock Incentive Plan, as amended from time to time (the “Plan”), as set forth in the Award Agreement;

 

WHEREAS, capitalized
terms used but not defined herein shall have the meanings ascribed to them in the Plan;

 

WHEREAS, pursuant
to Section 4.2 of the Plan, the Committee has the authority to modify existing Awards;

 

WHEREAS, on April
24, 2015, the Committee approved an amendment to all outstanding Awards granted to non-employee members of the Company’s
Board of Directors extending the exercise period following a Termination of Employment (or Service) for any reason to two (2) years
(the “Extended Exercise Period”); and

 

WHEREAS, Company
and Optionee desire to enter into this Amendment in order to restate Section 7 of the Award Agreement to reflect the Extended Exercise
Period.

 

NOW, THEREFORE, the parties hereto hereby
agree as follows:

 

1.          Section 7 of the Award Agreement is hereby amended and restated in its entirety as follows:

 

“7. Termination
of Employment (or Service).

 

(a) If
the Optionee has a Termination of Employment (or Service) for any reason other than death or Disability, the Optionee may at
any time within the two (2) year period after the date of his or her Termination of Employment (or Service) exercise the
Option to the extent that the Optionee was entitled to exercise the Option at the date of Termination of Employment (or
Service), provided that in no event shall the Option be exercisable after the Expiration Date.

 

(b)          If the
Optionee has a Termination of Employment (or Service) by reason of his death or Disability the Option will lapse on the earlier
of (i) the Option’s expiration date, or (ii) two (2) years after the date Termination of Employment (or Service) on account
of Disability or death. The Option may be exercised following the death or Disability of Optionee only if the Option was exercisable
by Optionee immediately prior to his or her death or Disability. In no event shall the Option be exercisable after the Expiration
Date.

 

2.          The
remaining terms and conditions of the Award Agreement shall survive this Amendment and will continue in full force and effect.

 

    	1

    	 

    

 

IN WITNESS WHEREOF,
the Company has caused this Amendment to be executed by its duly authorized representative and Optionee has signed this Amendment,
and this Amendment shall be effective as of the day and year first written above.

 

 

	
         

         

         

        __________________________

        Date
	
        Peregrine Pharmaceuticals, Inc. 

         

        By:__________________________

        Name:________________________

        Title:_________________________

         

         

         

         

        _____________________________

        Optionee

 

 

 

    	2Exhibit 10.2

 

TERMINATION AGREEMENT

 

THIS TERMINATION AGREEMENT (the “Agreement”)
is entered into as of June 4, 2015, by and between Moxian China, Inc., a Nevada corporation (the “Company”) and Zhongtou
Huifeng Investment Management (Beijing) Co. Ltd. (“Zhongtou”), a corporation formed pursuant to the laws of People’s
Republic of China. Each of the parties of the Agreement is referred to as “Party,” and collectively, the “Parties.”

 

WHEREAS, on April
24, 2015, the Company entered into a Subscription Agreement with Zhongtou (the “Subscription Agreement”), for a private
placement of 8,190,000 shares of its common stock, par value $0.001 per share (the “Common Stock”) to be issued to
Zhongtou at a per share price of $1.00 for gross proceeds of $8,190,000 and for no additional consideration an additional warrant
to purchase an aggregate of 32,000,000 shares of the Company’s Common Stock at an exercise price of $2.00 per share, exercisable
on or prior to July 31, 2015; and

 

WHEREAS, Zhongtou’s
principals have determined to make the same investment described above through a different entity;

 

WHEREAS, the Company
and Zhongtou therefore desire to terminate the Subscription Agreement;

 

NOW, THEREFORE,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as
follows:

 

Section 1.          Termination.The Company
and Zhongtou hereby agree that effective on the date hereof that the Subscription Agreement shall be terminated and be of no further
force or effect.

 

Section 2.           Waiver and Release of Obligations.

 

(a)         Each of the Parties agrees that any and all obligations of the other under the Subscription Agreement is hereby waived and
terminated and of no further effect.

 

(b)         Upon the execution of this Agreement, Zhongtou and its assigns, successors, subsidiaries, affiliates, owners, members, predecessors,
agents, representatives, officers, directors, and employees forever release and discharge the Company’s assigns, successors,
subsidiaries, affiliates, owners, shareholders, predecessors, agents, representatives, officers, directors, and employees from
any and all causes of action, actions, judgments, liens, damages, losses, claims, liabilities, and demands whatsoever, whether
known or unknown, which each other had, now has, or hereafter can, shall, or may have, however arising, including by reason of
any duty, breach, act, omission, condition or occurrence through and including the date of this Agreement and/or by reason of any
fact, act, matter, cause or thing of any kind whatsoever.

 

    	 

    	 

    

 

Section 3.           Miscellaneous.

 

(c)         Expenses. Each Party shall bear its own costs and expenses, including legal fees, incurred or sustained in connection
with the preparation of this Agreement and related matters.

 

(d)         Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended,
modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall
be in writing and signed by the Company and Zhongtou.

 

(e)         Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted
assigns of each of the parties.

 

(f)          Execution and Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together
shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and
delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature
is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create
a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect
as if such facsimile or “.pdf” signature page were an original thereof.

 

(g)         Governing Law. This Agreement shall be enforced, governed by and construed in accordance with the laws of the State
of Nevada applicable to agreements made and to be preformed entirely with such State, without regard to the principles of conflict
of laws.

 

(h)         Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result
as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
of such that may be hereafter declared invalid, illegal, void or unenforceable.

 

(i)          Headings. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and
shall not be deemed to limit or affect any of the provisions hereof.

 

[Signature Pages Follow]

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties hereof
have as of the date first written above executed this Agreement.

 

MOXIAN CHINA, INC.

 

	By:	 	 
	Name:	James Mengdong Tan	 
	Title:   	CEO & President	 

  

Zhongtou Huifeng Investment

Management (Beijing)
Co. Ltd.

 

	By:	 	 
	Name:	 	 
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}]]